1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Other Metabolic Disorders - Pipeline Review, H2 2013

Other Metabolic Disorders - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 39 pages

Other Metabolic Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Other Metabolic Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Metabolic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Metabolic Disorders. Other Metabolic Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Metabolic Disorders.
- A review of the Other Metabolic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Metabolic Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Metabolic Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Metabolic Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Other Metabolic Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Other Metabolic Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Other Metabolic Disorders 7
Other Metabolic Disorders Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Other Metabolic Disorders Therapeutics - Products under Development by Companies 13
Companies Involved in Other Metabolic Disorders Therapeutics Development 14
Obio Pharmaceutical Holdings Limited. 14
The Alize Pharma Group 15
Other Metabolic Disorders - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
KP-624 - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
AZP-01 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
UX-007 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
XAF-5 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
CAS-001 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
CAS-003 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
CAS-045 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Other Metabolic Disorders Therapeutics - Drug Profile Updates 28
Other Metabolic Disorders Therapeutics - Discontinued Products 30
Other Metabolic Disorders Therapeutics - Dormant Products 31
Other Metabolic Disorders - Product Development Milestones 32
Featured News and Press Releases 32
Aug 28, 2013: Ultragenyx Announces Presentation of two Abstract at the 12th International Congress of Inborn Errors of Metabolism (ICIEM 2013) 32
Aug 26, 2013: Ultragenyx Investigational New Drug Application for UX007 is Active 32
Aug 05, 2013: Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) 33
Jan 11, 2012: Bridge BioResearch Announces Completion Of Preclinical Trials Of 2hydroxyoleic Acid 34
Nov 01, 2011: KYTHERA Announces Preliminary Two-Year Follow-Up Study Results And Poster Presentation Of Phase IIb Data From Fat Reduction Drug At ASDS 34
Apr 14, 2011: CHMP Announces Positive Opinion For Carbaglu In Hyperammonaemia 34
Feb 15, 2011: Raptor To Enroll Five Additional Patients In Phase III Clinical Trial Of DR Cysteamine For Treatment Of Nephropathic Cystinosis 35
Feb 04, 2011: Kythera Reports Positive Results From Phase IIB Study With ATX-101 36
Oct 06, 2010: Arena And Eisai Report Lorcaserin Presentations At Obesity 2010 36
Oct 04, 2010: Orexigen Announces Upcoming Data Presentations At 28th Annual Scientific Meeting Of Obesity Society 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39



List of Tables

Number of Products Under Development for Other Metabolic Disorders, H2 2013 7
Products under Development for Other Metabolic Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Obio Pharmaceutical Holdings Limited., H2 2013 14
The Alize Pharma Group, H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Stage and Molecule Type, H2 2013 20
Other Metabolic Disorders Therapeutics - Drug Profile Updates 28
Other Metabolic Disorders Therapeutics - Discontinued Products 30
Other Metabolic Disorders Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Other Metabolic Disorders, H2 2013 7
Products under Development for Other Metabolic Disorders - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Discovery and Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 16
Assessment by Route of Administration, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Molecule Type, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 20



Companies Mentioned

Obio Pharmaceutical Holdings Limited.
The Alize Pharma Group

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2016

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline ...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016’, provides ...

Atherosclerosis - Pipeline Review, H2 2016

Atherosclerosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Atherosclerosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis – Pipeline Review, H2 2016, provides an overview ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.